These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 19967756)
1. Commentary on 'Designs for dose-escalation trials with quantitative responses'. Rosenberger WF; Manukyan Z Stat Med; 2009 Dec; 28(30):3751-3; discussion 3759-60. PubMed ID: 19967756 [No Abstract] [Full Text] [Related]
2. Commentary on 'Designs for dose-escalation trials with quantitative responses'. Atkinson AC Stat Med; 2009 Dec; 28(30):3739-41; discussion 3759-60. PubMed ID: 19967753 [No Abstract] [Full Text] [Related]
3. Commentary on 'Designs of dose-escalation trials with quantitative responses'. Haines LM Stat Med; 2009 Dec; 28(30):3742-4; discussion 3759-60. PubMed ID: 19967751 [No Abstract] [Full Text] [Related]
4. Commentary on 'Designs for dose-escalation trials with quantitative responses'. O'Quigley J Stat Med; 2009 Dec; 28(30):3745-50; discussion 3759-60. PubMed ID: 19967752 [TBL] [Abstract][Full Text] [Related]
5. Commentary on 'Designs for dose-escalation trials with quantitative responses'. Senn S Stat Med; 2009 Dec; 28(30):3754-8; discussion 3759-60. PubMed ID: 19967754 [No Abstract] [Full Text] [Related]
6. Designs for dose-escalation trials with quantitative responses. Bailey RA Stat Med; 2009 Dec; 28(30):3721-38. PubMed ID: 19579226 [TBL] [Abstract][Full Text] [Related]
7. Choice of designs and doses for early phase trials. Zhou Y Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290 [TBL] [Abstract][Full Text] [Related]
8. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity. Wang M; Day R J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253 [TBL] [Abstract][Full Text] [Related]
9. Improved up-and-down designs for phase I trials. Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752 [TBL] [Abstract][Full Text] [Related]
10. Adaptive designs for Phase I dose-finding studies. Zhou Y Fundam Clin Pharmacol; 2010 Apr; 24(2):129-38. PubMed ID: 19703268 [TBL] [Abstract][Full Text] [Related]
11. How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. Buoen C; Bjerrum OJ; Thomsen MS J Clin Pharmacol; 2005 Oct; 45(10):1123-36. PubMed ID: 16172177 [TBL] [Abstract][Full Text] [Related]
12. Escalation, group and A + B designs for dose-finding trials. Ivanova A Stat Med; 2006 Nov; 25(21):3668-78. PubMed ID: 16381057 [TBL] [Abstract][Full Text] [Related]
13. Optimal designs for estimating the most successful dose. Zohar S; O'Quigley J Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893 [TBL] [Abstract][Full Text] [Related]
14. Phase I trials: from traditional to newer approaches part II. Macaluso M; Krams M; Preskorn SH J Psychiatr Pract; 2011 Jul; 17(4):277-84. PubMed ID: 21775829 [TBL] [Abstract][Full Text] [Related]
15. Concentration-controlled trials. What does the future hold? Johnston A; Holt DW Clin Pharmacokinet; 1995 Feb; 28(2):93-9. PubMed ID: 7736691 [No Abstract] [Full Text] [Related]
16. Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials. Lledó-García R; Hennig S; Karlsson MO Clin Pharmacol Ther; 2009 Jul; 86(1):62-9. PubMed ID: 19339964 [TBL] [Abstract][Full Text] [Related]
17. Study design and rationale of a mock phase I trial as an educational tool for clinical pharmacology residents. Malhotra S; Shafiq N; Chandra KK; Pandhi P; Grover A Contemp Clin Trials; 2006 Apr; 27(2):183-7. PubMed ID: 16344002 [TBL] [Abstract][Full Text] [Related]